Please log in to view this page
Username
Password
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
This purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquiline (BDQ) in...
